Ross Dixon Selected Research

OC 144-093

8/2005	A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
4/2002	Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ross Dixon Research Topics

Disease

3	Neoplasms (Cancer) 08/2005 - 01/2002
1	Febrile Neutropenia 08/2005
1	Neutropenia 08/2005
1	Epilepsy (Aura) 01/2002

Drug/Important Bio-Agent (IBA)

2	OC 144-093IBA 08/2005 - 04/2002
2	Paclitaxel (Taxol)FDA LinkGeneric 08/2005 - 04/2002
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 08/2005
1	Antineoplastic Agents (Antineoplastics)IBA 04/2002
1	Biological ProductsIBA 04/2002
1	EnzymesIBA 01/2002
1	multidrug resistance-associated protein 1IBA 01/2002
1	Multidrug Resistance-Associated ProteinsIBA 01/2002

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 04/2002
1	Therapeutics 04/2002
1	Polypharmacy 01/2002